Good point. There is some evidence that APRIL levels are inversely correlated with disease activity (see reference below). Consequently, it may not be an advantage to inhibit APRIL or the BLYS/APRIL heterodimer. Time and clinical trials will tell.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.